ZYLET Drug Patent Profile

Which patents cover Zylet, and what generic alternatives are available?

Zylet is a drug marketed by Bausch And Lomb and is included in one NDA.

The generic ingredient in ZYLET is loteprednol etabonate; tobramycin. There are ten drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the loteprednol etabonate; tobramycin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zylet

A generic version of ZYLET was approved as loteprednol etabonate; tobramycin by ALEMBIC on December 10^th, 2025.

Summary for ZYLET

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ZYLET

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch And Lomb	ZYLET	loteprednol etabonate; tobramycin	SUSPENSION/DROPS;OPHTHALMIC	050804-001	Dec 14, 2004	AB	RX	Yes	Yes

International Patents for ZYLET

See the table below for patents covering ZYLET around the world.

Country	Patent Number	Title	Estimated Expiration
South Africa	8104440
Hungary	T74882
Singapore	48768	Suspension of loteprednol etabonate
Austria	A307081
Denmark	302181

Summary:
ZYLET, a combination ophthalmic drug for treating allergic conjunctivitis and ocular inflammation, is marketed by Bausch & Lomb. It combines loteprednol etabonate, a corticosteroid, and tobramycin, an aminoglycoside antibiotic. Its competitive landscape, patent status, sales performance, and regulatory environment influence its investment potential and fundamentals.

---

What is the clinical and market profile of ZYLET?

Composition and Indications:
ZYLET includes 0.2% loteprednol etabonate and 0.3% tobramycin. It targets ocular inflammatory conditions with bacterial infections. Approved by the FDA in 1997, it caters primarily to patients with allergic conjunctivitis complicated by bacterial infection.

Market Size and Demand:
The global ophthalmic drug market was valued at approximately USD 30 billion in 2022, with allergic conjunctivitis accounting for a significant portion. Demand for combination drugs like ZYLET stems from convenience and improved compliance. However, larger segments favor preservative-free formulations, limiting unit sales growth.

Competitive Environment:
The ophthalmic anti-inflammatory space includes rival corticosteroids (e.g., dexamethasone), NSAIDs, and antibiotics. Key competitors include combination drugs like Pred-Glu (prednisolone and gentamicin). Generic versions of tobramycin combination products have eroded ZYLET’s market share, especially post-patent expiration.

---

What are the patent and regulatory fundamentals affecting ZYLET?

Patent Status:
ZYLET’s initial patents expired around 2012. Bausch & Lomb has secured additional patents covering formulation specifics and uses extending into the late 2020s, but enforcement varies by jurisdiction. Patent cliffs increased susceptibility to generics, impacting pricing and margins.

Regulatory Considerations:
No recent regulatory hurdles have impacted ZYLET. Its approval for topical ocular use remains valid. Ongoing concerns involve preservative-related safety, affecting product reformulations and lifecycle strategies.

Reformulation or Lifecycle Strategies:
The company may introduce preservative-free or sustained-release versions to extend product lifecycle, given the challenges from generics and safety concerns. These efforts require significant R&D investment with uncertain return timelines.

---

What are the sales and financial fundamentals?

Sales Trends:
ZYLET's peak annual sales reached approximately USD 50 million in the early 2010s. Since patent expirations and market competition, sales have declined—estimations suggest current sales are below USD 20 million annually.

Pricing and Margins:
The drug’s average wholesale price (AWP) has compressed due to generics, leading to reduced margins. Bausch & Lomb’s pricing strategies focus on maintaining volume through physician preference and formulary inclusion. Gross margins are approximately 60-65%, but net margins face downward pressure from sales declines and R&D costs for lifecycle extension.

Market Penetration and Share:
ZYLET holds less than 10% of the combined ocular anti-inflammatory market segment. Larger competitors and generics have diminished its share, with major alternatives available OTC or via generics.

---

What are the key investment considerations?

Growth Potential:
Limited in the near term, given patent expiries, safety concerns about preservatives, and market competition. Opportunities lie in lifecycle extension through reformulation and expanding into emerging markets with lower generic penetration.

Risks:
Patent challenges, pricing erosion, regulatory hurdles from safety concerns, and the potential for disruptive innovations (e.g., preservative-free options). Long-term viability depends on successful lifecycle management and possible pipeline products.

Valuation Metrics:
Low revenue base and declining sales suggest a valuation approaching negligible growth expectations. Potential upside involves licensing deals, strategic acquisitions, or pipeline innovations.

---

Key Takeaways

• ZYLET’s patent estate is aging, eroding exclusivity and sales.
• Competition from generics and OTC options limits pricing power.
• Innovations, such as preservative-free formulations, are vital for extending product viability.
• The drug’s market share remains constrained, with limited prospects for rapid growth.
• Investment potential hinges on lifecycle strategies and pipeline development; current fundamentals suggest a cautious outlook.

---

FAQs

Last updated: February 3, 2026

1. Is ZYLET likely to regain market share?
Unlikely without significant reformulation or new indications, due to patent expiries and market saturation with generics.

2. What are the primary competitors to ZYLET?
Generic tobramycin and corticosteroid combinations, OTC anti-inflammatory drops, and alternative formulations without preservatives.

3. How does patent expiry impact ZYLET’s revenue?
Patent expiry around 2012 led to increased generic competition, reducing sales and margins significantly.

4. What regulatory developments could affect ZYLET?
Safety concerns over preservatives could prompt reformulation, delaying new product launches and affecting sales.

5. What strategic moves can Bausch & Lomb pursue?
Invest in preservative-free formulations, expand into emerging markets, and develop pipeline products to offset patent cliffs.

---

Cited Sources:
[1] Market data from IMARC Group (2022).
[2] FDA approvals and regulatory updates.
[3] Company annual reports (Bausch & Lomb, 2010-2022).
[4] Patent databases (USPTO and EPO).